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Abstract Antineoplasic agents such as cisplatin and adriamycin
execute their pharmacological role by triggering apoptosis. We
have studied the mechanism of apoptosis induction by cisplatin
and adriamycin. Both drugs activated JNK with slow and
persistent kinetics. Adriamycin activated caspase-3 before the
rise in JNK activity, while the response to cisplatin occurs hours
after JNK activation. The increase in JNK activity was
necessary for cisplatin-mediated apoptosis but it was dispensable
for adriamycin-induced cell death. Cells derived from c-jun
knock out mice were more resistant to cisplatin cell death than
normal cells, but no difference was observed in response to
adriamycin. Activation of JNK and cell death by cisplatin is
mediated by the MEKK1/SEK1 cascade, since expression of
dominant negative expression vectors of these kinases blocked
both processes. p38 was also activated by cisplatin with similar
kinetics as JNK. AP-1 complexes were activated by cisplatin
including mainly c-jun/ATF-2 heterodimers suggesting that
AP-1-dependent transcription partially mediated cisplatin-in-
duced apoptosis.
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1. Introduction
Antineoplasic agents such as cisplatin, etoposide, adriamy-
cin and taxol carry out their pharmacological role by eliciting
the apoptosis program in the cells. Recent evidence indicates
that the principal e¡ectors of apoptosis are a series of pro-
teases called caspases which inactivate proteins involved in
DNA repair and apoptosis protection [1] and activate proteins
involved in apoptosis induction [2]. Most antineoplasic agents
also activate di¡erent kinase cascades, such as the stress-acti-
vated protein kinase JNK/SAPK [3] that phosphorylates the
c-jun transcription factor at Ser-63 and Ser-73 [4] within its
transactivation domain [4^6]. The JNK/SAPK has also been
shown to phosphorylate and regulate the activity of other
transcription factors including ELK-1 and ATF-2 [4,5,7^9].
JNK/SAPK is a component of a sequential protein kinase
pathway [3,5,7,10^14] that similar to the ERK members of
the MAPK family requires phosphorylation for its enzymatic
activation. Its phosphorylation state is positively controlled by
JNK kinase (JNKK/stress-activated ERK kinase, SEK1)
[3,10,15,16]. JNKK/SEK1 is itself regulated by phosphoryla-
tion by an upstream kinase referred to as MEK kinase
(MEKK) [14] or alternatively ASK-1 [17]. A third MAPK
isoform is p38, that is activated in response to cellular stress
and osmotic shock by phosphorylation in a Tyr and Thr
residue and phosphorylates, among others, the ATF-2 tran-
scription factor [10,12,18].
c-jun forms, together with the Fos family of proteins, the
AP-1 transcription factor which has been implicated in a num-
ber of biological processes [19]. c-Jun-related proteins, JunB
and JunD, can also function as transcription factors either as
homodimers or bound to partner proteins, such as ATF-2,
CREB or Fos-related proteins [20,21]. c-Jun is rapidly and
transiently activated in response to mitogens, indicating that
c-Jun probably has a function in the control of cell prolifer-
ation [22^25]. In agreement with this hypothesis, cells lacking
a functional c-jun allele grow slower in vivo and in vitro [26^
28]. On the other hand, an increased c-Jun activity is able to
induce apoptosis in immortalized NIH3T3 ¢broblasts [29].
The consequences of JNK activation on cell fate seem to be
dependent on the type of stimuli. In cells treated with UVC
[30], JNK activation seems to have a protective e¡ect and in
response to other stimuli, such as TNF-K [31] or CD45 [32], it
does not play a role in apoptosis. On the contrary, in cells
committed to apoptosis by treatment with antineoplasic
agents, such as cisplatin, vincristin or adriamycin, JNK is
also activated, although its role on apoptosis is not well-es-
tablished. We show in this article that although both cisplatin
and adriamycin activate JNK and caspases, the ¢nal role of
JNK on the cell fate is di¡erent. Whilst in cells treated with
cisplatin, activation of the JNK pathway is necessary for casp-
ase activation and apoptosis induction, in cells treated with
adriamycin, activation of JNK occurs after caspase activation
and it is dispensable for apoptosis induction. These di¡erences
could have important implications in the therapeutic applica-
tion of both compounds.
2. Materials and methods
2.1. Cell lines, antibodies, plasmids and reagents
The epidermal keratinocyte cell line Pam 212 and human embryonic
kidney 293T cells were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium containing 4.5 g/l glucose and supplemented with 10% fetal calf
serum and 1 mM L-glutamine. NIH3T3 cells derived from c-jun knock
out mice were cultured in the same medium but supplemented with
5% fetal calf serum. Rabbit anti-JNK1 serum (anti-C-terminal do-
main), anti-p38 (AA 341-360), anti-c-Jun (C-terminal domain), anti-
c-Fos (amino-terminal domain), anti-ATF-2 (carboxi-terminal do-
main) and anti-PARP (N-terminal) were from Santa Cruz Biotechnol-
ogy. Plasmids pMEKK1, pMEKK1(K-R), pSEK1 and pSEK1(K-R)
were obtained from Michael Karin [33]. NIH3T3 cells derived from
knock out mice for c-jun were obtained from Erwin Wagner [27,34].
Jun3/+ cells were obtained by co-transfecting Jun3/3 cells with the
vector pCDNAI-c-jun and the p-PUR plasmid (Clontech) by the cal-
cium phosphate method and selecting stable transfectants by puromy-
cin resistance.
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2.2. Cell treatments
Cells were cultured at a density of 106 cells by a 100 mm plate and
subjected to di¡erent treatments. For the UV irradiation, cells were
shifted into medium containing 0.5% FBS during 24 h, the medium
was then removed and cells were irradiated with 40 J/m2 by using a
UV germicidal lamp. For cisplatin and adriamycin (Sigma) treat-
ments, after culturing during 24 h in 0.5% FBS, cells were incubated
with the drugs during the periods of time indicated in each experi-
ment.
2.3. Transient transfections and L-galactosidase assays
Cells were plated 24 h before transfection at a density of 3U105
cells/60 mM plate as previously described [35]. Cells were co-trans-
fected with the plasmids pCMVL-galactosidase and plasmids encoding
the dominant negative mutants MEKK1-KR and SEK1-KR. For
kinase assays, cells were incubated in 0.5% FCS during 24 h and
treated with cisplatin for 6 h and the e⁄ciency of transfection was
estimated by assaying for L-galactosidase activity. For the death as-
say, cells were transfected as before and allowed to recover during 8^
10 h in complete medium and then treated with cisplatin. Cells were
harvested at 20 h after treatment, washed and ¢xed in 1% glutaralde-
hyde in phosphate-bu¡ered saline (PBS) and then washed twice. Fixed
cells were then incubated in reaction solution (PBS pH 7.4, 1 mM
MgCl2, 10 mM K4(Fe(CN)4), 10 mM K3(Fe(CN)4) and 1 mM X-gal)
for 1 h and washed twice with PBS. Apoptotic cells were identi¢ed
by their shrunk morphology and intense staining. The person deter-
mining the percentage of apoptotic cells was not aware of the treat-
ment.
2.4. Extract preparation and solid phase kinase assays
Whole cell extract preparations for JNK assays were carried out as
described [36]. 20^40 Wg of extract was incubated with GST-c-jun-79
fusion protein bound to agarose beads and incubated in the presence
of 1 WCi [Q-32P]ATP in 30 Wl kinase bu¡er. The kinase reaction was
performed at 30‡C for 30 min and stopped with one volume of SDS
sample bu¡er. For the p38 MAPK assay, cells were lysed as described
[36] and p38 MAPK was immunoprecipitated with speci¢c antibody/
protein A-Sepharose (Pharmacia). Immunoprecipitates were subjected
to in vitro kinase assays by using puri¢ed GST-ATF-2 as the sub-
strate. Reactions were carried out during 30 min at 30‡C. The reaction
mixtures were resolved by SDS-PAGE analysis. The amount of radio-
activity incorporated in each lane was determined with an instantim-
ager (Packard) and corrected against the amount of peptide in each
lane as determined by gel staining with Coomassie blue.
2.5. Cell viability assay
The cell viability was determined by using a crystal violet staining
method as previously described [36]. For propidium iodide staining,
cells were treated as indicated [36], propidium iodide was added at a
concentration of 10 WM during 10 min and the cells were directly
visualized under a Zeiss microscope at a 630-fold magni¢cation.
2.6. Western blot analysis
30 Wg of total cellular protein was subjected to SDS-PAGE, trans-
ferred to nitrocellulose and immunoblotted with a 1:1000 dilution of
either anti-JNK1, anti c-Jun or anti-PARP antibodies. Immunocom-
plexes were visualized by enhanced chemiluminescence detection
(Amersham) using a biotinylated anti-rabbit antibody and peroxi-
dase-coupled streptavidin.
2.7. Gel retardation analysis
Cells were serum depleted during 24 h and whole cell extracts ob-
tained as described [20]. Gel retardation analysis was performed as
described [37] using double-stranded oligonucleotides containing the
sequences 5P-AGCTGGGGTGACATCATGGG-3P (JUN1: c-jun nu-
cleotides 375^360), 5P-AGCTAGCATTACCTCATCCC-3P (JUN2:
c-jun nucleotides 3194^3179). 5 Wg of whole cell extract was incu-
bated with 5U104 cpm of 32P-labelled probe for 30 min at 4‡C and
the complexes were separated in a 4% polyacrylamide gel in 0.5UTris-
borate-EDTA bu¡er. To test the e¡ect of speci¢c antibodies, 1 Wl
antiserum was added to the incubation mixture for 30 min at 4‡C
prior to the addition of labelled probe. The binding speci¢city was
con¢rmed by competition with a 100-fold excess of non-labelled
JUN1, JUN2 or SP1 (5P-GATGTGTGGGAGGAGCTTCT-3P) oligo-
nucleotides.
3. Results
3.1. c-jun contributes to cisplatin- but not adriamycin-induced
apoptosis
c-jun is phosphorylated in response to activation of JNK by
antineoplasic drugs, such as cisplatin [36] and adriamycin [38].
In order to elucidate if activation of the JNK pathway is
necessary for apoptosis induction by these drugs, we have
used immortalized 3T3 ¢broblasts derived from mouse em-
bryos without c-jun, due to targeted disruption of the c-jun
gene by homologous recombination [27]. This cell line shows
an increased sensitivity to certain types of stress such as UVC
radiation [34]. We ¢rst examined whether the absence of c-jun
a¡ects the cell survival after exposure to di¡erent doses of
cisplatin. As it can be observed in Fig. 1a, cells lacking
c-jun were more resistant to cisplatin than parental cells.
The ID50 for jun3/3 cells was 10-fold higher than that ob-
tained with the wild-type cells. The increased viability ob-
served in jun3/3 cells could be due to an unspeci¢c clonal
Fig. 1. Cell viability after cisplatin and adriamycin treatment of cells
lacking the c-jun gene. NIH3T3 cells derived from control mice
(WT), knock out mice for c-jun (jun3/3) or jun3/3 cells trans-
fected with c-jun (jun3/+) were treated at di¡erent concentrations
of cisplatin (a) or adriamycin (b) for 48 h and the viability was esti-
mated by a crystal violet-based staining method. Inserted is a West-
ern blot showing the expression levels of c-jun in each cell line. The
data represent the means of a single experiment performed in tripli-
cate. The experiment was repeated twice with similar results.
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e¡ect of this cell line. To check this possibility, we have gen-
erated the cell line jun3/+, by transfecting the c-jun gene into
the jun3/3 cell line (Fig. 1a). Although Jun3/+ cells ex-
pressed lower levels of c-jun than the wild-type, as determined
by a Western blot analysis, the sensitivity to cisplatin is higher
than that of the jun3/3 cell line, indicating that a lack of c-
jun was indeed the cause of the increased viability to cisplatin
of the jun3/3 cells. On the contrary, when we tested the
sensitivity of jun3/3 or parental cells to adriamycin, we ob-
served no detectable di¡erences. We then studied the activa-
tion of JNK of both cell lines to cisplatin and adriamycin. As
shown in Fig. 2, both compounds were able to activate JNK
in both cell lines in a similar fashion and intensity. The only
di¡erence observed in the parental cell was a delayed JNK
activation in response to adriamycin, reaching the maximal
activation at 6 h after drug addition, in contrast to cisplatin
that reached the peak at 3 h.
3.2. Caspase-3/CPP32 activity is not required for activation of
the JNK pathway by cisplatin but is necessary for
apoptosis induction
Increasing evidence in the literature indicates that the pro-
teolytic cleavage of critical subcellular substrates by the casp-
ase family of proteases [39^41] plays an important role in the
executionary phase of the apoptotic process [42]. This family
of proteinases cleaves their target proteins behind an aspartic
acid [42^45] in a speci¢c sequence. During apoptosis, a dis-
crete set of cellular proteins becomes cleaved by ICE/CED-3-
related proteinases, including poly(ADP-ribose) polymerase
(PARP), DNA-dependent protein kinase (DNA-PK), protein
kinase CN(PKCN) and others (reviewed in [39]). In order to
investigate the di¡erence observed in sensitivity of jun3/3
Fig. 2. JNK activation in response to cisplatin and adriamycin.
NIH-derived cell lines from control animals (WT) or derived from
jun3/3 animals were serum-depleted during 24 h and treated with
(a) cisplatin (10 Wg/ml) or (b) adriamycin (1 Wg/ml). Cell lysates
were used for determination of the JNK activity (upper panels) by
the agarose-coupled GST-c-Jun kinase assay or subjected to a West-
ern blot (lower panels) for analysis of (a) c-jun or (b) JNK expres-
sion. The experiment was repeated twice with similar results.
Fig. 3. Caspase-3 activity in cisplatin- and adriamycin-treated cells.
Control WT or Jun3/3 cells were treated with (a) cisplatin (10 Wg/
ml) or (b) adriamycin (1 Wg/ml). Extracts were prepared at di¡erent
times after treatment and a Western blot was performed with a pol-
yclonal antibody directed against PARP. The full length protein
(116 kDa) is designed as PARPFL. The 85 kDa proteolytic frag-
ment is indicated with an arrow.
Fig. 4. Caspase-3 activity is not necessary for JNK activation by
cisplatin. (a) JNK activity after caspase-3 inhibition. Pam 212 cells
were serum-harvested during 24 h and treated with 10 Wg/ml cispla-
tin. When indicated, cells were pretreated with DEVD-CHO (100
WM). At di¡erent time points, cells were collected and the lysate
was assayed for JNK expression and activation by Western immu-
noblotting using a polyclonal antiserum against JNK1. The arrows
indicate the unphosphorylated or phosphorylated (P) forms of
JNK1. The experiments were repeated twice with similar results. (b)
Apoptosis detection by propidium iodide staining. Pam 212 cells
were stimulated with cisplatin after pretreatment with DEVD (1 h
at 100 WM) in normal medium or not and stained with propidium
iodide. The apoptotic cells were quanti¢ed by £uorescence micros-
copy.
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cells to cisplatin in contrast to adriamycin, we studied the
timing of caspase activation in response to both drugs. Cleav-
age of PARP was used as an assay for caspase-3 (CPP32)
activity. Both parental and jun3/3 cells responded to cispla-
tin and adriamycin by cleaving PARP (Fig. 3). However, we
observed signi¢cant di¡erences in the kinetics of caspase-3
activation in response to both drugs. While activation induced
by cisplatin (Fig. 3a) was detected 9 h after drug addition,
adriamycin activates caspase-3 3 h after treatment. Similar
results were obtained by using a speci¢c substrate for
CPP32, DEVD-AMC (data not shown).
Recently, it has been demonstrated that MEKK1 is a sub-
strate for caspase-3, that cleaves this protein at Asp-874 [2].
Proteolytic cleavage at this site generates a COOH-terminal
fragment encoding the MEKK1 kinase domain [46]. Previous
reports indicated that genotoxins, such as UVC induce pro-
teolytic degradation of MEKK1, a few hours after DNA
damage [47]. We then tested if activation of JNK by both
drugs could be in£uenced by the activity of caspase-3. As
shown in Fig. 4a, treatment of Pam 212 cells with cisplatin
alone or after 1 h pretreatment with DEVD-CHO (an inhib-
itor of caspase-3) showed no detectable inhibition in JNK
activation at any time after treatment. Similar results were
obtained with adriamycin, in agreement with previous results
[48]. By contrast, activation of apoptosis by cisplatin (Fig. 4b)
and adriamycin (not shown) could be inhibited by DEVD-
CHO. As caspase-3 is activated in response to adriamycin
before JNK is activated, the results suggest that activation
of JNK in response to this drug is not necessary for apoptosis
induction.
3.3. Activation of JNK and cell death by cisplatin is dependent
on the MEKK1 and SEK1 activities
Since c-jun seems to participate in apoptosis induction by
cisplatin, we studied the pathway involved in JNK activation
by this drug. Activation of JNK in response to several agents
is elicited through activation of a cascade of kinases [49] that
includes MEKK1/SEK1. We have used transient transfection
assays in 293T cells in order to examine the e¡ect of expres-
sion of the dominant negative mutants for MEKK1(KR) and
SEK1(KR) on JNK activation in response to cisplatin (Fig.
5). Although expression of MEKK1 or SEK1 slightly en-
hanced JNK activation in response to cisplatin, expression
of either MEKK1(KR) or SEK1 (KR) prevented in a dose-
dependent manner JNK activation by this drug without af-
fecting the levels of JNK protein (Fig. 5). In conclusion, the
results indicate that activation of JNK by cisplatin involves
and requires the MEKK1-SEK1 pathway.
We then tested if interfering with the MEKK1/SEK1/JNK
pathway had a suppressive e¡ect on apoptosis. 293T or Pam
212 cells were transfected with the pCMVL-galactosidase plas-
mid alone or together with plasmids encoding the dominant
negative kinase mutants and the cells were treated with cis-
platin. After 20 h, the cells were harvested and stained with X-
gal to analyze the L-galactosidase expressing cells (blue color).
The survival rate of transfected cells after drug treatment was
estimated by monitoring the cell morphology among the blue
cells. Cells were assigned as apoptotic when they were exhib-
iting a shrunk cell shape. The dominant negative mutants of
MEKK1 and SEK1 enhanced cell survival of transfected Pam
212 (Fig. 6a) or 293T cells (not shown). In both cell lines,
Fig. 5. Cisplatin requires MEKK1 for activation of JNK. 293T cells were transiently transfected with the indicated amounts of DNA encoding
the wild-type or the dominant negative forms of MEKK1 or SEK1 kinases. Cells were then serum-depleted during 24 h and treated with cispla-
tin (10 Wg/ml) during 6 h. The transfection e⁄ciency was monitored by transfecting in parallel a plate with pCMVL-galactosidase which was
stained for enzymatic activity. Endogenous JNK was measured in cell extracts by using agarose beads coupled to puri¢ed GST-c-jun protein.
(a) The quanti¢cation in an instantimager of a typical experiment where the amount of the radioactivity incorporated in each sample was re-
lated to the vector-untreated sample, considered as one. (b) Autoradiogram of the samples quanti¢ed in a. In the lower panel, a Western blot
of JNK of the samples. The data represent the means of a single experiment performed in triplicate. The experiment was repeated twice with
similar results.
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apoptosis was reduced by more than 50% in cells transfected
with the kinase defective mutants (Fig. 6b). These results in-
dicate that interfering with the JNK pathway partially pre-
vents mortality induced by cisplatin, suggesting that this path-
way contributes to cell death.
3.4. AP-1 complexes induced by cisplatin contain c-Fos, c-Jun
and ATF-2 proteins
Our results indicated that c-Jun protein levels are increased
in cisplatin-treated cells (Fig. 2). Transfection of an expression
vector encoding a dominant negative c-jun mutant Flag v169
[50] resulted in protection to apoptosis induction by cisplatin
(data not shown). These results are consistent with the idea
that phosphorylation of the c-Jun protein at its N-terminal
transactivation domain by JNK is one of the events involved
in apoptosis induction, since its deletion partially protects cells
to cisplatin. These results suggested that de novo transcription
is required for this process. In agreement with these hypoth-
esis, treatment of Pam 212 cells with actinomicin D, an inhib-
itor of RNA synthesis, partially protected them from death
induced by cisplatin treatment (data not shown), suggesting
that cisplatin induces transcription of genes that could be
involved in apoptosis.
Since activation of c-Jun is required for apoptosis, we wish
to elucidate which types of AP-1 complexes were induced
upon cisplatin treatment. We have used the AP-1 sites found
at the c-jun promoter [37,46] for this study. Both sites, named
JUN1 and JUN2, have been found to contribute to UV-medi-
ated induction of c-jun transcription in several cell types [37].
Extracts from Pam 212 cells treated with cisplatin (Fig. 7)
showed a transient increase (3 h) in the amount of AP-1
complexes, bound to the JUN1 oligo. To identify the nature
of factors bound to this site, we pre-incubated nuclear extracts
with speci¢c antibodies against c-Jun, c-Fos or ATF-2. The
results indicated that the complexes were mainly composed
from c-Jun and c-Fos. We have also used extracts from cells
irradiated with UVC (40 J/m2) and also detected a transient
increase in the amount of these complexes although at shorter
intervals after treatment (1 h). A di¡erent kinetic was ob-
tained when we used an oligo corresponding to the JUN2
site. Cisplatin induced an increase in the amount of these
complexes that is permanent up to 9 h of treatment and con-
tained mainly c-Jun and ATF-2 proteins (Fig. 7a, b). As ob-
served with the JUN1 site, the increase in the amount of
complexes bound to this oligo was transient when we treated
the cells with UVC. These results are in agreement with pre-
vious results indicating that cisplatin induces an increase in c-
Jun protein that persists during at least 12 h after drug addi-
tion. Additionally, we have observed an increase in p38 activ-
ity that showed the same kinetic of activation as JNK in
response to cisplatin (Fig. 7c). The parallel increase in both
activities could, therefore, explain the continuous increase in
AP-1 complexes containing c-Jun and ATF-2. AP-1 com-
plexes are involved in upregulation of the c-jun promoter
[37] but in addition, these complexes could be necessary for
the induction of de novo transcription of genes involved in
cell death.
Fig. 6. Apoptosis induced by cisplatin involves activation of the MEKK1/SEK1 pathway. Pam 212 and 293T cells were transiently transfected
with 5 Wg of the indicated plasmid and 1 Wg of pCMV-L-galactosidase. Transfected cells were incubated in complete medium, treated with the
indicated concentrations of cisplatin and processed for L-galactosidase activity. In (a), Pam 212 cells were transfected and the apoptotic cells
were identi¢ed as indicated in Section 2. (b) Quanti¢cation of experiments described in (a), performed in Pam 212 (upper panel) or 293T cells
(lower panel). Data are reported as the percentage of apoptotic cells among the total blue cells. An average of 400 cells were examined in dif-
ferent ¢elds for each plate. The data represent the means of a single experiment performed in triplicate. The experiments were repeated twice
and similar results were obtained.
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4. Discussion
Pathological disturbance of the balance among cell growth
and apoptosis often leads to an imbalance in the cell number
and could lead to tumorigenesis [51]. Thus, manipulation of
the signal pathways that control apoptosis has emerged as an
important strategy for anti-cancer therapy. Additionally, sev-
eral anti-cancer drugs (cisplatin, etoposide, adriamycin) exert
their therapeutical action by inducing apoptosis in the treated
cells. Therefore, determining the intracellular pathways acti-
vated by these drugs could improve clinical protocols. In these
studies, we present evidence demonstrating that interfering
with the SAPK pathway and the transcriptional activity of
the c-Jun protein increased the survival to cisplatin.
Our results support evidence from other laboratories indi-
cating that the role of the JNK pathway in apoptosis depends
on the genotoxic agent. By using two di¡erent anti-neoplasic
drugs that activate JNK, we have found that this enzyme is an
important mediator of apoptosis induced by cisplatin but not
by adriamycin. We observed that mouse ¢broblasts lacking
the c-jun gene were more resistant to cisplatin than normal
cells, while jun3/+ cells recover sensitivity to cisplatin. By
contrast, no di¡erence was found when the cells were treated
with adriamycin similarly to the results observed with other
DNA damaging agents such as UVC [37]. Our results suggest
that in cisplatin-treated cells, induction of apoptosis can take
place as a consequence of JNK activation. In cells treated
with adriamycin, caspases are probably activated throughout
a di¡erent pathway that does not require JNK activation as
described for Fas-induced apoptosis [32].
We have observed that not only JNK but also p38 MAPK
is activated in cells treated with cisplatin. Activation of both
cell signaling cascades has been involved in response to other
DNA damaging agents, such as UVC, MMS and gamma
radiation [52]. Our results showed that activation of JNK in
response to cisplatin involves the activity of the sequential
MEKK1 and SEK1/MEKK4 kinase cascade. Activation of
this cascade by cisplatin takes place in the absence of other
survival pathways, such as activation of the ERK cascade [36]
and promotes cell death. Since interfering with the MEKK1
pathway does not totally block apoptosis induced by cisplatin,
it is reasonable to suggest that other parallel pathways such as
ASK-1 [17] would be induced by cisplatin. In other situations,
there may be other intracellular pathways regulated by JNK
activation. For example, it has been described that in some
systems, activation of JNK pathways may be a part of a DNA
repair and cell survival mechanism [53].
Since the main intracellular target described for JNK is the
Fig. 7. Analysis of AP-1 complexes induced by cisplatin. Pam 212 cells were serum-depleted during 24 h and treated either with 10 Wg/ml cis-
platin or irradiated with 40 J/m2 and harvested at the indicated times. Total extracts were obtained and incubated with 32P-labelled oligonu-
cleotides corresponding to the JUN1 (upper panel) or JUN2 (lower panel) AP-1 sites of the c-jun promoter. When indicated (Comp.), samples
from cells treated during 3 h (upper) or 6 h (lower) with cisplatin were incubated with antibodies speci¢c for ATF-2, c-Jun or c-Fos. Extracts
from UV-treated cells were subjected to competition with oligonucleotides containing either JUN1, JUN2 or Sp1 sites. (b) DNA-bound com-
plexes from cisplatin-treated cells speci¢c to JUN1 and JUN2 sites were quanti¢ed and represented in relation with untreated cells. The experi-
ments were repeated twice with similar results.
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c-Jun protein, our results suggest that modulating the activity
of this protein would have some e¡ect in cisplatin-mediated
apoptosis. Treatment of cells with inhibitors of gene expres-
sion, such as actinomicin D, has a protective e¡ect in cells
treated with cisplatin, suggesting that de novo gene expression
is necessary for triggering the apoptotic process. In contrast
with these results, Fas-induced apoptosis does not require new
gene expression or protein synthesis and in this system,
although JNK is activated, it is not necessary for apoptosis
[32]. The results obtained using a dominant negative construc-
tion for c-jun that lacks the transactivation domain indicate
that transcriptional activation of this protein contributes to
cisplatin-induced apoptosis. In agreement with these results,
expression of a c-jun gene lacking the transactivation domain
is also able to protect sympatetic neurons against pro-
grammed cell death induced by NGF withdrawal [50]. We
observed that AP-1 complexes that contained mainly c-Jun
and ATF-2 proteins were induced after cisplatin treatment
and remained high up to 6 h after treatment. These results
are in agreement with the cisplatin-induced activation of both
JNK and p38 with similar kinetics. On the other hand, AP-1
complexes containing c-Fos and c-jun increased with transient
kinetics suggesting that AP-1 complexes containing c-Jun and
ATF-2 could be involved in inducing the transcription of
death genes. In agreement with these results, an increase in
AP-1 complexes has also been reported to correlate with
apoptosis in several physiological processes, such as involu-
tion of the mouse mammary gland and the rat prostate in vivo
upon hormone depletion [54,55] or in response to DNA dam-
aging agents [56^58].
Our results may have important implications in cancer
chemotherapy with cisplatin. In addition to its toxic side
e¡ects, a major limitation in cancer chemotherapy is drug
resistance. Our results suggest that deletions of genes encoding
some of the proteins involved in transducing the death signal
throughout the JNK cascade would result in increasing resist-
ance to cisplatin, as occurs in the jun3/3-derived cells. Sup-
porting this hypothesis, it has recently been reported that in
knock out animals for JNK3, excitotoxicity fails to induce
apoptosis in the hypocampus [59]. In a di¡erent study [60],
it has been found that tumoral cell lines derived from pancre-
atic, lung, breast and colon carcinomas showed deletions in
the encoding regions of the MKK4/SEK1 gene. These ¢ndings
indicate that MKK4 may function as a suppressor of tumori-
genesis by triggering apoptosis in response to stress and its
mutations could contribute to drug resistance.
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